You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for Patent: 5,210,085


✉ Email this page to a colleague

« Back to Dashboard


Title: Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
Abstract:The present invention relates to a method of preparing the antiviral compounds 2'-deoxy-5-fluoro-3'thiacytidine (FTC) and various prodrug analogues of FTC from inexpensive precursors with the option of introducing functionality as needed; methods of using these compounds, particularly in the prevention and treatment of AIDS; and the compounds themselves. This synthetic route allows the stereoselective preparation of the biologically active isomer of these compounds and related compounds.
Inventor(s): Liotta; Dennis C. (Stone Mountain, GA), Schinazi; Raymond F. (Decatur, GA), Choi; Woo-Baeg (North Brunswick, NJ)
Assignee: Emory University (Atlanta, GA)
Filing Date:Feb 22, 1991
Application Number:07/659,760
Claims:1. A method for treating a human having an HIV infection comprising administering to the human an effective HIV-treatment amount of a compound of the formula: ##STR9##

2. The method of claim 1, wherein the pharmaceutically acceptable derivative comprises a monophosphate, diphosphate, or triphosphate ester of 2'-deoxy-5-fluoro-3'-thiacytidine.

3. The method of claim 1, wherein the pharmaceutically acceptable carrier comprises a liposomal suspension.

4. A method for treating a human having an HIV infection comprising administering to the human an effective HIV-treatment amount of a .beta.-isomer of a substituted 2'-deoxy-5-fluoro-3'-thiacytidine having the formula: ##STR10## wherein Y is independently selected from the group consisting of H, alkyl, substituted alkyl, cycloalkyl and acyl; and

R is selected from the group consisting of H, hydroxyl, oxyacyl, monophosphate, diphosphate, and triphosphate.

5. The method of claim 4, wherein the substituted 2'-deoxy-5-fluoro-3'-thiacytidine is selected from the group consisting of the monophosphate, diphosphate, and triphosphate ester of 2'-deoxy-5-fluoro-3'-thiacytidine.

6. The method of claim 4, wherein the pharmaceutically acceptable carrier comprises a liposomal suspension.

7. The method of claim 4, wherein the .beta.-isomer of the substituted 2'-deoxy-5-fluoro-3'-thiacytidine is selected from the group consisting of 4-N-acetyl-2'-deoxy-5-fluoro-3'-thiacytidine; 4-N-acetyl-5'-butyryl-2'-deoxy-5-fluoro-3'-thiacytidine; and 5'-butyryl-2'-deoxy-5-fluoro-3'-thiacytidine.

8. A method for treating a human having an HIV infection comprising administering to the human an effective HIV treatment amount of a compound of the formula: ##STR11## wherein Y is monophosphate, diphosphate, or triphosphate.

9. A method for treating a human having an HIV infection comprising administering to the human an effective HIV-treatment amount of a compound of the formula: ##STR12## wherein Y is independently selected from the group consisting of H, alkyl, cycloalkyl, and acyl; and

R is selected from the group consisting of H, hydroxyl, oxyacyl, monophosphate, diphosphate, and triphosphate.

10. A method for treating a human having an HIV infection comprising administering to the human an effective HIV-treatment amount of a pharmaceutically acceptable salt of a compound of the formula: ##STR13##

11. A method for treating a human having an HIV infection comprising administering to the human an effective HIV-treatment amount of the pharmaceutically acceptable salt of .beta.-isomer of a substituted 2'-deoxy-5-fluoro-3'-thiacytidine having the formula: ##STR14## wherein Y is independently selected from the group consisting of H, alkyl, substituted alkyl, cycloalkyl and acyl; and

R is selected from the group consisting of H, hydroxy, oxyacyl, monophosphate, diphosphate, and triphosphate.

12. A method for treating a human having an HIV infection comprising administering to the human an effective HIV-treatment amount of a pharmaceutically acceptable salt of a compound of the formula: ##STR15## wherein Y is monophosphate, diphosphate, or triphosphate.

13. A method for treating a human having an HIV infection comprising administering to the human an effective HIV treatment amount of the pharmaceutically acceptable salt of a compound of the formula: ##STR16## wherein Y is independently selected from the group consisting of H, alkyl, cycloalkyl and acyl; and

R is selected from the group consisting of H, hydroxyl, oxyacyl, monophosphate, diphosphate, and triphosphate.

14. The method of claim 1, wherein the compound is administered in a pharmaceutically acceptable carrier.

15. The method of claim 4, wherein the compound is administered in a pharmaceutically acceptable carrier.

16. The method of claim 8, wherein the compound is administered in a pharmaceutically acceptable carrier.

17. The method of claim 9, wherein the compound is administered in a pharmaceutically acceptable carrier.

18. The method of claim 10, wherein the compound is administered in a pharmaceutically acceptable carrier.

19. The method of claim 11, wherein the compound is administered in a pharmaceutically acceptable carrier.

20. The method of claim 12, wherein the compound is administered in a pharmaceutically acceptable carrier.

21. The method of claim 13, wherein the compound is administered in a pharmaceutically acceptable carrier.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.